$19.51
0.00%
Nasdaq, Aug 30, 12:01 am CET
ISIN
US80810D1037
Symbol
SDGR

Schrodinger Inc Stock price

$19.51
-1.66 7.84% 1M
-2.80 12.55% 6M
+0.22 1.14% YTD
-1.69 7.97% 1Y
-7.59 28.01% 3Y
-40.95 67.73% 5Y
-9.13 31.88% 10Y
-9.13 31.88% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.25 1.27%

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$985.9m
Net debt
positive
Cash
$450.2m
Shares outstanding
73.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.0 | 5.6
EV/Sales
4.1 | 3.8
EV/FCF
40.5
P/B
4.2
Financial Health
Equity Ratio
51.2%
Return on Equity
-44.4%
ROCE
-36.2%
ROIC
-144.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$237.9m | $256.7m
EBITDA
$-186.5m | $-188.8m
EBIT
$-192.9m | $-202.7m
Net Income
$-181.3m | $-175.7m
Free Cash Flow
$24.4m
Growth (TTM | estimate)
Revenue
18.6% | 23.7%
EBITDA
7.0% | 7.1%
EBIT
6.3% | 3.2%
Net Income
10.0% | 6.1%
Free Cash Flow
112.7%
Margin (TTM | estimate)
Gross
58.5%
EBITDA
-78.4% | -73.6%
EBIT
-81.1%
Net
-76.2% | -68.4%
Free Cash Flow
10.2%
More
EPS
$-2.5
FCF per Share
$0.3
Short interest
23.9%
Employees
891
Rev per Employee
$230.0k
Show more

Is Schrodinger Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Schrodinger Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Schrodinger Inc forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Schrodinger Inc forecast:

Buy
80%
Hold
20%

Financial data from Schrodinger Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
238 238
19% 19%
100%
- Direct Costs 99 99
43% 43%
42%
139 139
6% 6%
58%
- Selling and Administrative Expenses 143 143
4% 4%
60%
- Research and Development Expense 189 189
5% 5%
80%
-186 -186
7% 7%
-78%
- Depreciation and Amortization 6.44 6.44
18% 18%
3%
EBIT (Operating Income) EBIT -193 -193
6% 6%
-81%
Net Profit -181 -181
10% 10%
-76%

In millions USD.

Don't miss a Thing! We will send you all news about Schrodinger Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Schrodinger Inc Stock News

Neutral
Business Wire
6 days ago
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live presentation will take place on Monday, September 8, 2025 at 11:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approxima...
Neutral
Business Wire
17 days ago
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors ...
Neutral
Business Wire
19 days ago
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1...
More Schrodinger Inc News

Company Profile

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.

Head office United States
CEO Ramy Farid
Employees 891
Founded 1990
Website www.schrodinger.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today